In addition, we found that the synergistic combination of EZM2302 and anti-PD-1 treatment substantially increased the susceptibility to immunotherapy in NSCLC patients with high circHMGB2 expression. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.